Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Metrics to compare | ELVN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipELVNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −16.3x | −0.7x | −0.6x | |
PEG Ratio | −3.81 | −0.01 | 0.00 | |
Price/Book | 3.3x | 1.8x | 2.6x | |
Price / LTM Sales | - | 9.5x | 3.4x | |
Upside (Analyst Target) | 46.2% | 19.9% | 44.9% | |
Fair Value Upside | Unlock | 31.4% | 6.3% | Unlock |